Drugmakers still confused by CFR-21 parts 210 and 211, says West

By Gareth Macdonald

- Last updated on GMT

Since coming into effect late last year, US Code of Federal Regulations-21 parts 210 and 211 testing rules have been the subject of much confusion in the pharmaceutical industry, according to West Pharmaceutical Services.

At Interphex 2009 in New York,US Outsourcing-pharma spoke with industry expert Jennifer Riter of West Pharmaceutical Services about the scope of the CFR-21 parts 210 and 211 as they apply to microbiology, de-pyrogenation processing and batch closure regulations.

Riter also talked about how well the pharmaceutical industry has adapted to the new good manufacturing practice (GMP) standards and explained how West can help its customers understand and comply with the rules with its line of ready-to-steralise components.

Related news

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars